Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10382453" target="_blank" >RIV/00216208:11140/18:10382453 - isvavai.cz</a>
Alternative codes found
RIV/00669806:_____/18:10382453 RIV/00023001:_____/18:00077447
Result on the web
<a href="https://doi.org/10.1186/s12879-018-3493-y" target="_blank" >https://doi.org/10.1186/s12879-018-3493-y</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s12879-018-3493-y" target="_blank" >10.1186/s12879-018-3493-y</a>
Alternative languages
Result language
angličtina
Original language name
Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial
Original language description
Background: Cytomegalovirus (CMV) prophylaxis may prevent CMV indirect effects in renal transplant recipients. This study aimed to compare the efficacy of valganciclovir and valacyclovir prophylaxis for CMV after renal transplantation with the focus on chronic histologic damage within the graft. Methods: From November 2007 through April 2012, adult renal transplant recipients were randomized, in an open-label, single-center study, at a 1:1 ratio to 3-month prophylaxis with valganciclovir (n=60) or valacyclovir (n=59). The primary endpoint was moderate-to-severe interstitial fibrosis and tubular atrophy assessed by protocol biopsy at 3 years evaluated by a single pathologist blinded to the study group. The analysis was conducted in an intention-to-treat population. Results: Among the 101 patients who had a protocol biopsy specimen available, the risk of moderate-to-severe interstitial fibrosis and tubular atrophy was significantly lower in those treated with valganciclovir (22% versus 34%; adjusted odds ratio, 0.31; 95% confidence interval, 0.11-0.90; P=0.032 by multivariate logistic regression). The incidence of CMV disease (9% versus 2%; P=0.115) and CMV DNAemia (36% versus 42%; P=0.361) were not different at 3 years. Conclusions: Valganciclovir prophylaxis, as compared with valacyclovir, was associated with a reduced risk of moderate-to-severe interstitial fibrosis and tubular atrophy in patients after renal transplantation.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
<a href="/en/project/LO1503" target="_blank" >LO1503: BIOMEDIC</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BMC Infectious Diseases
ISSN
1471-2334
e-ISSN
—
Volume of the periodical
18
Issue of the periodical within the volume
November
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
573-580
UT code for WoS article
000450531600004
EID of the result in the Scopus database
2-s2.0-85056632792